$-0.24 EPS Expected for Oramed Pharmaceuticals Inc. (ORMP)

January 3, 2018 – By Dolores Ford

Investors sentiment decreased to 2 in Q3 2017. Its down 4.00, from 6 in 2017Q2. It worsened, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 2 reduced holdings. 2 funds opened positions while 6 raised stakes. 255,973 shares or 20.44% less from 321,734 shares in 2017Q2 were reported.
Barclays Public Limited Com stated it has 41,186 shares or 0% of all its holdings. Jfs Wealth Advsrs Ltd Liability Company invested in 0% or 500 shares. Royal Comml Bank Of Canada holds 500 shares or 0% of its portfolio. Renaissance Technologies Lc holds 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 83,000 shares. Plante Moran invested in 0% or 300 shares. New York-based Morgan Stanley has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 14,725 are held by Wells Fargo Co Mn. Pnc Financial Serv Group reported 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Tower Rech Cap Ltd Limited Liability Company (Trc) reported 393 shares or 0% of all its holdings. Susquehanna International Grp Llp owns 18,762 shares. Comml Bank Of Montreal Can, Ontario – Canada-based fund reported 1,600 shares. Bancshares Of America Corporation De holds 0% or 1,117 shares. Jpmorgan Chase And stated it has 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). One Trading L P holds 7,605 shares. 20,000 are owned by Glenmede Trust Com Na.

Since August 2, 2017, it had 0 insider purchases, and 1 insider sale for $761,906 activity.

Analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report $-0.24 EPS on January, 10.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. The stock decreased 1.28% or $0.1165 during the last trading session, reaching $9.0035. About 7,597 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has risen 2.79% since January 3, 2017 and is uptrending. It has underperformed by 13.91% the S&P500.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Ratings Coverage

Among 4 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals has $25 highest and $15 lowest target. $22.25’s average target is 147.13% above currents $935 stock price. Oramed Pharmaceuticals had 9 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 22. H.C. Wainwright initiated it with “Buy” rating and $24 target in Thursday, October 1 report. FBR Capital initiated the stock with “Outperform” rating in Thursday, November 19 report. The rating was initiated by Rodman & Renshaw on Friday, October 2 with “Buy”. Zacks upgraded the shares of ORMP in report on Friday, August 14 to “Sell” rating. H.C. Wainwright maintained Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) on Thursday, October 5 with “Buy” rating. The firm has “Buy” rating by B. Riley & Co given on Monday, December 11. The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has “Buy” rating given on Tuesday, December 1 by H.C. Wainwright.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $128.81 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

More notable recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Seekingalpha.com which released: “Oramed: The Atypical Biotechnology Company With Great Upside Potential” on July 01, 2016, also Quotes.Wsj.com with their article: “Oramed Pharmaceuticals Inc.” published on February 11, 2013, Seekingalpha.com published: “Oramed: Progress On Oral Insulin Pill” on July 27, 2016. More interesting news about Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were released by: Prnewswire.com and their article: “Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study” published on May 18, 2016 as well as Prnewswire.com‘s news article titled: “Oramed Appoints Dr. Roy Eldor as Chief Medical Director” with publication date: July 26, 2016.